350 filings
D
VNRX
VolitionRX Ltd
26 Mar 24
$100.00 k in equity, sold $100.00 k, 1 investor
11:14am
10-K
2023 FY
VNRX
VolitionRX Ltd
Annual report
25 Mar 24
4:19pm
8-K
VNRX
VolitionRX Ltd
25 Mar 24
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
4:15pm
8-K
VNRX
VolitionRX Ltd
19 Mar 24
Volition appoints Dr Andrew Retter as Chief Medical Officer
4:37pm
UPLOAD
VNRX
VolitionRX Ltd
3 Jan 24
Letter from SEC
12:00am
8-K
6zync g91
2 Jan 24
Other Events
8:00am
CORRESP
0wt8vkf 9c5jm
20 Dec 23
Correspondence with SEC
12:00am
UPLOAD
ta7erf2fjbj57d4g
15 Dec 23
Letter from SEC
12:00am
8-K
d7ts4lovpuv2hvdk3
5 Dec 23
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
8:07am
8-K
ycdyt ing2
14 Nov 23
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
4:16pm
8-K
yew85mnn4b
14 Aug 23
VolitionRx Limited Announces Second Quarter 2023 Financial
4:18pm
S-8
h91oxfu8vn7x7f1u099
14 Jul 23
Registration of securities for employees
4:57pm
8-K
yolbc hy69d69dsfq1
30 Jun 23
Departure of Directors or Certain Officers
4:05pm
8-K
4gl2popyr56x6cbu
2 Jun 23
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
9:56pm
424B5
p3954spkx6
2 Jun 23
Prospectus supplement for primary offering
5:12pm
424B5
hup8 zf9snkhfgurn4
31 May 23
Prospectus supplement for primary offering
4:56pm
8-K
hrckit1i8ip7ef
10 May 23
VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update
4:17pm